Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
[US Stock Movement] Savara Surges on November 19: FDA Approval Approaching, High Short Interest, and Clinical-Stage Biopharmaceutical Company

[US Stock Movement] Savara Surges on November 19: FDA Approval Approaching, High Short Interest, and Clinical-Stage Biopharmaceutical Company

Bitget异动解读Bitget异动解读2026/11/19 19:01
Show original

Savara November 19th Major Surge Interpretation

Keywords: FDA approval approaching, high short interest, clinical-stage biopharma company

1. Media reports on November 16th indicated that the U.S. Food and Drug Administration (FDA) is expected to make a decision on November 22nd regarding the Biologics License Application for MOLBREEVI for autoimmune pulmonary alveolar proteinosis. JPMorgan previously gave the stock an overweight rating and set a target price of $12.

2. Data from November 18th shows that approximately 32.27 million Savara shares have been sold short, accounting for about 24.87% of the float. Based on recent trading volume, the estimated days to cover is approximately 12.94 days.

3. The company is a clinical-stage biopharmaceutical enterprise, and its only pipeline project, MOLBREEVI, is an inhaled granulocyte-macrophage colony-stimulating factor for autoimmune pulmonary alveolar proteinosis. It has submitted marketing applications in the U.S., EU, and UK, which are currently under review.

(Disclaimer: This content is summarized and generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!